Perspective
Would ending some drug rebates for PBMs lower list prices and patient out-of-pocket-costs? Our pharmacy experts Mckenzie Taylor & Stephanie Tran explore a proposed rule from the Department of Health and Human Services that would change the Medicare & Medicaid pricing system.
Pharmacists play a vital role in the patient care process that is often overlooked. Clinical pharmacy expert Ashley Chiara blogs about how they connect the dots between prescribers and patients, impacting clinical and economic outcomes.
Comprehensive care for children – including greater attention to behavioral health, socio-emotional development, and strong family relationships – may hold the key to lifelong health and well-being.
Prohibiting gag clauses could help lower consumer out-of-pocket pharmacy costs - if Pharmacy Benefits Managers don't raise prices to make-up the difference. Mylissa Price closes our blog series on President Trump's Blueprint to Lower Drug Costs in this final entry.
Decoding the critical differences between state Medicaid programs can be a frustrating task for policymakers & researchers alike. Health policy expert Rachel Gershon simplifies things by shedding light on helpful informational resources in a new blog post.
The Trump Administration Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs calls for incentives to lower drug list prices, including removing rebates. Our clinical consultant Stephanie Tran continues our pharmacy blog series with an assessment of this potential change & its impacts.
Director of academic programs for the Health and Criminal Justice Program Warren Ferguson, shares the story of how he collaborated with Criminal Justice health experts from UMass Medical School & the Tufts Medical School to develop the first required curriculum on correctional health in the United States.
The health of vulnerable populations in Massachusetts, including children, could be affected by a proposed update to the Public Charge Rule. Senior Policy Analyst John Moreschi blogs about the impact as outlined in his issue brief for the Blue Cross Blue Shield of Massachusetts Foundation.
New Trump Administrations Section 1332 waiver guidance increases state ACA flexibility. Rachel Gershon & Catie Torri discuss what this could mean for health care policy.
Mckenzie Taylor continues our monthly conversation on the strategies presented in The Trump Administration Blueprint to Low Drug Prices and Reduce Out-of-Pocket Costs, discussing the ways new negotiations between payers and manufacturers are helping to reduce drug prices.